Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT5B | P51692 | 3/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096016 | 0.86 | STAT5B (0.81) | STAT5BSMN1; SMN2ALDH1A1TSHRHDAC6 | |
| SCHEMBL22096023 | 0.85 | STAT5B (0.65) | STAT5BDHODH | |
| SCHEMBL22096022 | 0.84 | STAT5B (0.81) | STAT5BALDH1A1TSHRHDAC6 | |
| SCHEMBL22096024 | 0.82 | STAT5B (0.79) | STAT5BALDH1A1HDAC6 | |
| SCHEMBL22096035 | 0.80 | STAT5B (0.72) | STAT5BSMN1; SMN2ALDH1A1LMNATSHR | |
| SCHEMBL22096043 | 0.80 | STAT5B (0.68) | STAT5BSMN1; SMN2ALDH1A1 | |
| SCHEMBL22096017 | 0.78 | STAT5B (0.65) | STAT5BSMN1; SMN2ALDH1A1TSHRHDAC6 | |
| SCHEMBL22096039 | 0.77 | STAT5B (0.77) | STAT5BSMN1; SMN2ALDH1A1HDAC6 | |
| SCHEMBL22096041 | 0.77 | STAT5B (0.56) | STAT5BALDH1A1LMNAHDAC6 | |
| SCHEMBL22096026 | 0.77 | STAT5B (1.00) | STAT5BALDH1A1LMNAHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523297-B1 | NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER | UNIV BERLIN FREIE (DE) | 2021-07-07 | — | — | EP | disclosed |
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FREIE UNIVERSITAET BERLIN (DE) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FLT3, MCL1, MYD88 | STAT5B 59/4885MRGPRX4 2986/4885NR1H4 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.